Aims & Scope:

Neurological and Psychiatric illnesses are among the biggest challenges faced by medicine today, particularly with regards to providing adequate therapies or medications to meet the patient’s needs. There is a plethora of medications with varied efficacy that expose millions of patients to a wide range of side effects, resulting in reservations about continued use. New therapies for different conditions are being evaluated in clinical trials in hopes of introducing better options in the treatment of CNS illnesses. This special issue will capture a deep understanding of the effects medications have on the CNS, and introduce new research on CNS therapeutics. The papers submitted to this special issue should bring a thorough review of the mechanisms involved in each therapy and discuss the new frontiers in treatment for the CNS condition under investigation. Discussion of pharmacogenomics, pharmacokinetics and neurochemistry is strongly advised.

The aim of this special issue is to explore the characteristics, mechanisms, and historical prospective on the evolution of drugs for various neurological conditions. In addition, we welcome clinical studies with outcomes and results that provide valuable insight into possible novel mechanisms and whether or not they effectively treat these conditions.

Preferred types of submissions are original studies, review articles, and clinical studies. However, any type of article that discusses the pharmacogenomics, pharmacokinetics, and neurochemistry and can bring deep discussion on CNS drugs used for diverse conditions including those listed is welcomed.
We aim to provide medical and scientific professionals a broad and up to date view on current treatments, their effects, and novel drug mechanisms being explored in clinical trials. We welcome multiple perspectives in order to enrich the special issue and make it beneficial to both the scientific and medical community with hopes to facilitating translation of effective CNS treatments and therapies into clinical practice.

**Topics to be covered (main bioactive component):**

1. Neurodegenerative Conditions
2. Stroke
3. Infections
4. Mood Disorders
5. Demyelinating Disease
6. Brain Trauma

**List of tentative titles to be included in theme issue:**

1. The role of gaseous molecules in traumatic brain injury
3. Norrin: A Potential Target for Hemorrhagic Stroke
4. Spotlight on Dopamine Agonist Therapy for Parkinson’s Disease and How to Manage its Adverse Effects

**Keywords:** Neurodegenerative Conditions, Stroke, Infections, Mood Disorders, Demyelinating Disease, Brain Trauma

**Schedule:**

May 2018.